3 recruiting, 1 not yet recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Not yet recruiting 1 |
Follow Immunoglobulin A Nephropathy (IgAN): new trials by email Literature Review of Immunoglobulin A Nephropathy (IgAN) trials Research Report on Immunoglobulin A Nephropathy (IgAN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | argenx | 120 | 2026-11-05 | 2026-10-27 |
| Chinese Adults With Kidney Disease ADX-038, Telitacicept - Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 30 | 2026-05-21 | 2026-09-03 |
| A Study to Assess the Effects of Zigakibart on IgA Nephropathy. zigakibart - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 32 | 2026-03-26 | 2026-10-21 |
| Efficacy and Safety Study of HS-10542 for IgA Nephropathy HS-10542 High Dose, HS-10542 Low Dose, Placebo - IgAN, Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 90 | 2026-03-17 | 2026-03-16 |
Glomerulonephritis, IGA (4) · Glomerulonephritis, Membranoproliferative (1) · Proteinuria (1)
Autoimmune Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Glomerulonephritis (4) · Immune System Diseases (4) · Kidney Diseases (4) · Male Urogenital Diseases (4) · Nephritis (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Urination Disorders (1) · Urological Manifestations (1)
telitacicept (1)
ADARx Pharmaceuticals, Inc. (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Novartis Pharmaceuticals (1) · argenx (1)
China (3) · Japan (2) · United States (2) · Brazil (1) · Czechia (1) · Germany (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1)
Arezoo Mirad (1)